Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Diabetic Neuropathy

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impaired processing of time-critical language information in Parkinson's disease.

Parkinsonism & related disorders·2026

Same author

Non-sensorimotor symptoms in chronic inflammatory demyelinating polyneuropathy.

Journal of neurology·2026

Same author

Attenuated melanopsin-mediated activity in focal dystonia.

Parkinsonism & related disorders·2026

Same author

Cognitive impairment in chronic inflammatory demyelinating polyneuropathy.

Journal of neurology·2025

Same author

Abnormal Sleep in Chronic Inflammatory Demyelinating Polyneuropathy.

European journal of neurology·2025

Same author

Motor and Cognitive Fatigue in Chronic Inflammatory Demyelinating Polyneuropathy.

European journal of neurology·2025

Search research articles

Related Experiment Video

Updated: May 30, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Malnutritional neuropathy under intestinal levodopa infusion.

Fabian Klostermann¹, Constanze Jugel, Thomas Müller

¹Deptartment of Neurology, CBF, Charité-University Medicine Berlin, Hindenburdamm 30, 12203 Berlin, Germany. fabian.klostermann@charite.de

Journal of Neural Transmission (Vienna, Austria : 1996)

|July 26, 2011

Summary

Levodopa/Carbidopa intestinal gel infusion (LCIG) may cause polyneuropathy (PNP) due to nutritional deficiencies. Vitamin replacement helped patients, suggesting LCIG-induced PNP is preventable with screenings and monitoring.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: May 30, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neurology
Gastroenterology
Nutritional Science

Background:

Parkinson's disease management often involves Levodopa/Carbidopa intestinal gel infusion (LCIG).
A potential side effect of LCIG is the development of polyneuropathy (PNP).

Observation:

Two out of twenty patients on LCIG developed severe axonal PNP.
These patients exhibited deficiencies in pyridoxine and folate, with low cobalamin levels.
Elevated homocysteine levels were noted in affected patients.

Findings:

LCIG treatment was associated with nutritional deficiencies potentially leading to PNP.
Vitamin replacement therapy effectively treated the induced neuropathies.
Homocysteine elevation may serve as a biomarker for LCIG-induced nutritional deficits.

Implications:

LCIG may provoke PNP, likely due to malnutritional factors.
Screening for predisposing factors before LCIG initiation is recommended.
Regular neurophysiological and laboratory monitoring are crucial to prevent LCIG-associated PNP.